Rhein Improves Renal Lesion and Ameliorates Dyslipidemia in db/db Mice with Diabetic Nephropathy

Abstract

Rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid) is purified from rhubarb (Rheum officinale), a widely used traditional Chinese herb. In our previous studies, rhein was shown to be effective in ameliorating diabetic renal pathological changes and attenuating hyperlipidemia. Statins have also been proven to ameliorate renal pathological changes associated with diabetic nephropathy (DN) through lipid-dependent and ‐independent mechanisms. We here study the protective and regulatory effects of rhein on renal injury and dyslipidemia in db/db mice with DN, using simvastatin as the control, and provide information on the mechanisms by which rhein protects against renal damage from DN. The results indicated that urinary albumin excretion (UAE) was reduced after 8 weeks of treatment in the rhein group, and 12 weeks in the simvastatin group. The morphometric analysis revealed that levels of extracellular matrix (ECM) significantly decreased in the rhein group after the full treatment course, but not in the simvastatin group. The more powerful effects of rhein on decreasing transforming growth factor-beta1 (TGF-β1) and fibronectin immunohistochemistry expression in renal tissue were also observed. And the plasma levels of cholesterol (Chol), triglyceride (TG), low-density lipoprotein cholesterol (LDL‐C) and ApoE all decreased in both the rhein and the simvastatin groups. Together, our data suggested that both rhein and simvastatin regulate dyslipidemia. The powerful effect of rhein in renal protection is due to its widespread effects. Rhein is a new drug that can decrease lipid levels and protect against DN progression in a different fashion with simvastatin.

Rheum officinale - Polygonaceae - rhein - simvastatin - diabetic nephropathy - dyslipidemia - db/db mice

References

• 1 Chen Q H. Experimental study and clinical application on rhubara.  Chin J Med Pharmacol. 1974;  8 226
• 2 He Z H, He M F, Ma S C, But P P. Anti-angiogenic effects of rhubarb and its anthraquinone derivatives.  J Ethnopharmacol. 2009;  121 313-317
• 3 Deffaud J, Kirchmeyer M, Domagala F, Ficheux H, Netter P, Bianchi A. Modulatory effect of rhein on IL-1α-induced responses in human chondrocytes: a comparative study between antibody microarrays and specific ELISAs.  Biorheology. 2008;  45 439-455
• 4 Lin M L, Chung J G, Lu Y C, Yang C Y, Chen S S. Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor.  Oral Oncol. 2009;  45 531-537
• 5 Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol J P. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK‐AP‐1 dependent pathways.  Clin Exp Rheumatol. 2007;  25 546-555
• 6 Chen J, Ma M, Lu Y, Wang L, Wu C, Duan H. Rhaponticin from rhubarb rhizomes alleviates liver steatosis and improves blood glucose and lipid profiles in KK/Ay diabetic mice.  Planta Med. 2009;  75 472-477
• 7 Zhu J M, Liu Z H, Huang Y F, Chen H P, Zhou H, Wang J P, Li L S. Therapeutic effect of rhein on diabetic nephropathy in db/db mice.  J Nephrol Dial Transplant. 2002;  11 3-10
• 8 Guo X H, Liu Z H, Peng A, Bi Y, Wang J P, Zhou H, Li L S. Rhein retards the progression of type 2 diabetic nephropathy.  Chin J Nephrol. 2002;  18 280-284
• 9 Jia Z H, Liu Z H, Zheng J M, Zeng C H, Li L S. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.  Exp Clin Endocrinol Diabetes. 2007;  115 571-576
• 10 Huang Y F, Liu Z H, Chen H P, Zhou H, Wang J P, Zhu M Y, Li L S. Improvement of diabetic metabolic disorders ameliorate the renal lesion in db/db mice: comparison between rhein and rosiglitazone.  J Nephrol Dial Transplant. 2004;  13 215-221
• 11 Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H. HMG‐CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.  Nephrol Dial Transplant. 2003;  18 265-272
• 12 Chen H C, Guh J Y, Chang J M, Hsieh M C, Shin S J, Lai Y H. Role of lipid control in diabetic nephropathy.  Kidney Int Suppl. 2005;  94 S60-S62
• 13 Kanwar Y S, Wada J, Sun L, Xie P, Wallner E I, Chen S, Chugh S, Danesh F R. Diabetic nephropathy: mechanisms of renal disease progression.  Exp Biol Med (Maywood). 2008;  233 4-11
• 14 Liu Z H, Li Y J, Chen Z H, Liu D, Li L S. Glucose transporter in human glomerular mesangial cells modulated by transforming growth factor-beta and rhein.  Acta Pharmacol Sin. 2001;  22 169-175
• 15 Liu Z H, Zhu J M, Huang H D, Chen Z H, Li L S. Effect of rhein on plasminogen activator inhibitor-1 expression of endothelial cells induced by transforming growth factor β1.  Chin J Nephrol. 2002;  18 337-341
• 16 Pan A, Sun J, Chen Y, Ye X, Li H, Yu Z, Wang Y, Gu W, Zhang X, Chen X, Demark-Wahnefried W, Liu Y, Lin X. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial.  PLoS ONE. 2007;  2 e1148
• 17 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 18 Macisaac R J, Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes.  Minerva Endocrinol. 2005;  30 161-177
• 19 Attia D M, Feron O, Goldschmeding R, Radermakers L H, Vaziri N D, Boer P, Balligand J L, Koomans H A, Joles J A. Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism.  J Am Soc Nephrol. 2004;  15 949-957
• 20 Dominguez J H, Tang N, Xu W, Evan A P, Siakotos A N, Agarwal R, Walsh J, Deeg M, Pratt J H, March K L, Monnier V M, Weiss M F, Baynes J W, Peterson R. Studies of renal injury III: lipid-induced nephropathy in type II diabetes.  Kidney Int. 2000;  57 92-104
• 21 Ji Z Q, Huang C W, Liang C J, Sun W W, Chen B, Tang P R. Effects of rhein on activity of caspase-3 in kidney and cell apoptosis on the progression of renal injury in glomerulosclerosis.  Chin J Med. 2005;  85 1836-1841
• 22 Shibutani S, Nagasawa T, Yokozawa T, Oura H. Effect of rhubarb (Rhei rhizoma) extract on urea nitrogen and amino acid metabolism after administration.  Yakugaku Zasshi. 1980;  100 434-442
• 23 Yokozawa T, Zheng P D, Oura H, Nishioka I. Urine composition in rats with adenine-induced renal failure during treatment with rhubarb extract.  Chem Pharm Bull (Tokyo). 1984;  32 205-212
• 24 Li L S. Rheum officinale: a new lead in preventing progression of chronic renal failure.  Chin Med J. 1996;  109 35-37
• 25 Fried L F, Orchard T J, Kasiske B L. Effect of lipid reduction on the progression of renal disease: a meta-analysis.  Kidney Int. 2001;  59 260-269
• 26 Mclaughlin K, Jardine A G. Clinical management of diabetic nephropathy.  Diabetes Obes Metab. 1999;  1 307-315
• 27 Zheng J M, Zhu J M, Li L S, Liu Z H. Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway.  Br J Pharmacol. 2008;  153 1456-1464
• 28 van Goor H, van der Horst M L, Atmosoerodjo J, Joles J A, van Tol A, Grond J. Renal apolipoproteins in nephrotic rats.  Am J Pathol. 1993;  142 1804-1812
• 29 Liu Z H, Zheng J M, Wu Y C, Zhu J M, Huang Y F, Li L S. Renal gene expression profiles of db/db mice and its alteration after the treatment with rhein.  J Nephrol Dial Transplant. 2002;  11 201-205
• 30 Danesh F R, Sadeghi M M, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar Y S. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p 21 signaling pathway: implications for diabetic nephropathy.  Proc Natl Acad Sci USA. 2002;  99 8301-8305
• 31 Guo X H, Liu Z H, Dai C S, Li H, Liu D, Li L S. Rhein inhibits renal tubular epithelial cell hypertrophy and extracellular matrix accumulation induced by transforming growth factor beta1.  Acta Pharmacol Sin. 2001;  22 934-938
• 32 Watts K L, Spiteri M A. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism.  Am J Physiol Lung Cell Mol Physiol. 2004;  287 L1323-L1332
• 33 Eberlein M, Heusinger-Ribeir O J, Goppelt-Struebe M. Rho-dependent inhibition of the induction connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).  Br J Pharmacol. 2001;  133 1172-1180
• 34 Evans T, Deng D X, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats.  Diabetes. 2000;  49 662-666